Table 2 BMD: stratified analysis of MSC-treated vs. control
From: Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis
| Â | Subgroup | N | Effect estimate | I2 | p* | p** |
|---|---|---|---|---|---|---|
Species of animals | Mice | 11 | 5.67 (3.78, 7.56) | 94% | p<0.00001 | p<0.0001 |
Rat | 5 | 0.34 (− 1.08, 1.76) | 88% | p<0.00002 |  | |
Swine | Not calculated | Â | Â | |||
Types of MSCs | BMSCs | 12 | 3.23 (1.63, 4.84) | 94% | p<0.00001 | P=0.76 |
Other MSCs | 5 | 2.86 (1.13, 4.60) | 87% | p<0.00001 | Â | |
Frequency of injection | Single injection | 14 | 2.20 (1.03, 3.37) | 92% | p<0.00001 | N |
Multiple injection | Not calculated | |||||
Time of injection | Before modeling | Not calculated | N | |||
At the same time of modeling | Not calculated | |||||
After modeling | 14 | 3.92 (2.59, 5.52) | 93% | p<0.00001 | ||
Bone diseases | Bone defect | 12 | 2.26 (0.99, 3.54) | 92% | p<0.00001 | p=0.05 |
Systematic bone diseases | 5 | 6.25 (2.45, 10.05) | 92% | p<0.00001 | Â | |
Sex of animals | Male | 6 | 3.64 (1.02, 6.27) | 96% | p<0.00001 | p=0.65 |
Female | 5 | 2.88 (0.90, 4.86) | 89% | p<0.00001 | Â | |